Moderna stock forfeits gains as first US bird flu death puts vaccine development in focus
Moderna stock was on track to see a weekly gain of 10% as of Wednesday following the first reported bird flu death in the US.
FDA Urges Guillain-Barré Syndrome Warning On Labels Of RSV Vaccines Abrysvo And Arexvy
The FDA has required the manufacturers of the RSV Vaccines Abrysvo and Arexvy to add a new warning to their labels about the ...
Berenberg Bank Sticks to Its Buy Rating for Resolute Mining Limited (RMGGF)
In a report released yesterday, Kerry Holford from Berenberg Bank maintained a Buy rating on Resolute Mining Limited (RMGGF – Research Report), ...
Becker's Hospital Review1d
FDA mandates warnings for 2 RSV vaccines
The FDA has mandated updated safety labeling for two respiratory syncytial virus vaccines, Pfizer's Abrysvo and GlaxoSmithKline's Arexvy, following the identification of an increased risk of ...
pharmaphorum1d
After GSK stumble, Pfizer moves forward with RSV vaccine
Pfizer has been awarded breakthrough status ... The news comes just days after GlaxoSmithKline called a halt to enrolment and vaccination in three trials of its RSV shot in pregnant women while ...
pharmaphorum4d
GSK poaches Pfizer exec Dormitzer as new vaccines R&D chief
GlaxoSmithKline has found a replacement for head of vaccines R&D Emmanuel Hanon, who left the company for a US biotech earlier this year, hiring Phil Dormitzer from ...
Hosted on MSN3d
Is there a vaccine for H5N1? What we know as first person with severe case of bird flu died in United States
The H5N1 bird flu has been reported to have caused the death of a patient in Louisiana. Such a case poses a significant ...
Moderna stock on track for 20% weekly gain after US bird flu death
Moderna stock was on track to see a weekly gain of over 20% as of Wednesday following the first reported bird flu death in the US.
Medpage Today on MSN2d
High Response Rate in Heavily Treated Multiple Myeloma With Novel Drug Combination
A novel combination for relapsed/refractory multiple myeloma produced responses in about 80% of a heavily treated population, ...
thebusinessmagazine17h
R&D expert joins board of Genomics
Ramos, previously Pfizer's senior vice president and global head of BioTherapeutics R&D, has been appointed to the board of ...
Future Market Insights3d
Pediatric Vaccine Industry to Reach USD 184,706.7 Million by 2033, Growing at a Remarkable CAGR of 13.1%
The global pediatric vaccine market is set for unprecedented growth, with a valuation of US$ 54,130.1 million in 2023, ...